Sanofi (NYSE:SNY) Reaches New 1-Year High at $45.70

Sanofi SA (NYSE:SNY) shares hit a new 52-week high during trading on Friday . The company traded as high as $45.70 and last traded at $45.65, with a volume of 27147 shares traded. The stock had previously closed at $44.92.

A number of equities analysts recently commented on the company. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Thursday, August 29th. UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Thursday, August 29th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Tuesday, August 6th. Finally, TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, June 21st. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $49.67.

The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The company’s fifty day moving average is $42.81 and its 200-day moving average is $42.81. The firm has a market capitalization of $114.43 billion, a P/E ratio of 14.53, a P/E/G ratio of 2.41 and a beta of 0.67.



Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 29th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.07. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business had revenue of $8.63 billion during the quarter, compared to the consensus estimate of $8.42 billion. During the same period in the prior year, the firm earned $1.25 EPS. Sanofi’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, equities research analysts anticipate that Sanofi SA will post 3.1 EPS for the current year.

In related news, major shareholder Sanofi acquired 93,750 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.00% of the company’s stock.

Large investors have recently modified their holdings of the business. Lazard Asset Management LLC lifted its stake in shares of Sanofi by 47,594.3% in the 1st quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock valued at $105,595,000 after purchasing an additional 2,379,716 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of Sanofi by 221.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,000 shares of the company’s stock valued at $55,602,000 after buying an additional 885,000 shares during the period. Morgan Stanley lifted its holdings in Sanofi by 34.1% in the 2nd quarter. Morgan Stanley now owns 3,145,435 shares of the company’s stock worth $136,104,000 after buying an additional 800,612 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Sanofi during the 2nd quarter valued at about $29,037,000. Finally, Schafer Cullen Capital Management Inc lifted its stake in shares of Sanofi by 106.8% in the 2nd quarter. Schafer Cullen Capital Management Inc now owns 728,871 shares of the company’s stock worth $30,088,000 after acquiring an additional 376,410 shares during the period. Institutional investors and hedge funds own 7.04% of the company’s stock.

Sanofi Company Profile (NYSE:SNY)

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Investing strategies using the yield curve

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.